A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic ...
Sep 4, 2019
0
2
In an Epilepsia analysis of 2008-2010 Medicare claims data, one in four older Americans with new-onset epilepsy and more than one-third with prevalent epilepsy received a combination of antiepileptic drugs and non-epilepsy ...
Feb 7, 2018
0
26
A team of scientists led by Dr Bhaskar Bhattacharya and Associate Professor Richie Soong from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) conducted a study on acquired ...
Sep 5, 2016
0
0
(HealthDay)—Zurampic (lesinurad) has been approved by the U.S. Food and Drug Administration to control blood levels of uric acid associated with gout.
Dec 23, 2015
0
1
Researchers have discovered details of the abnormal molecular signals and biological events that drive a high-risk form of the childhood cancer neuroblastoma. They aim to use these findings to develop more effective targeted ...
Oct 15, 2015
0
55
Breast cancer is the leading cause of cancer death in women around the world, responsible for 1,700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative ...
Jun 7, 2021
0
14
The rise in multi-drug resistant (MDR) and extremely drug resistant (XDR) strains of Mycobacterium tuberculosis (MTB) is becoming a major cause of global health concern for treating tuberculosis, which affects a third of ...
Jun 6, 2016
0
44
Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics ...
Sep 27, 2013
0
0
A new combination drug treatment has shown promising results in patients with pan-refractory, recurrent/metastatic head and neck cancer, according to a study published today in the Journal of Clinical Oncology.
Mar 28, 2023
0
2
(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.
Oct 31, 2011
0
0
